OriCell Therapeutics Raises Over $120 Million in Series B Financing Led by Qiming Venture Partners and Quan Capital to Advance Cell Therapies for Cancer Immunology

PR Newswire
August 1, 2022 — 22:00 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: America car China chinese Expansion healthcare investment manufacturing pharmaceutical Qiming Venture Partners Shanghai technology United States venture capital

Related News:

Cybellum Receives Frost & Sullivan’s Competitive Strategy Award for its Innovative Product Security Solutions

September 27, 2024 — 01:00

Iconic Supermodels Helena Christensen and Sean O’Pry Lead the NYFW Debut of E-commerce Powerhouses Ekouaer and Coofandy

September 14, 2024 — 20:26

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

September 14, 2024 — 08:18

Desay Battery Highlights Advanced Energy Solutions at RE+ 2024

September 11, 2024 — 03:00

Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results

August 29, 2024 — 14:31

Telin and Indosat Ooredoo Hutchison Partner to Develop the Indonesia Cable System Express 2 (ICE System 2)

August 28, 2024 — 20:46

LAZADA GROUP RELEASES ANNUAL ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) IMPACT REPORT FOR FINANCIAL YEAR 2024

August 27, 2024 — 11:00

Hyundai Motor Group Companies’ Ratings Upgraded by Global Top Rating Agencies

August 26, 2024 — 17:24

2024 Belt and Road Journalists Forum to Be Held in Chongqing

August 25, 2024 — 17:50

Franchising and Licensing Asia (FLAsia) 2024